Bill to legalize cannabis oil passes through Senate committee

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

Oklahoma State Capitol

OKLAHOMA CITY — A bill to legalize the use of cannabidiol, a derivative linked to marijuana, is heading to a vote of the full Senate after being unanimously approved in the Senate Health and Human Services committee yesterday by a vote of 9-0.

House Bill 2154, also known as Katie and Cayman’s Law, would legalize clinical trials using CBD to treat children and adults who suffer from epileptic seizures and help reduce the number and intensity of their seizures.

“Oklahoma has children who are suffering from different types of epileptic seizures and this bill allows the opportunity to be supportive of innovative treatments that could help them,” Senator Brian Crain (R-Tulsa) said.

State Rep. Jon Echols (R-Oklahoma City) emphasizes the bill is not an attempt to legalize marijuana, but an effort to help his niece and other children in the state who suffer from a variety of debilitating types of epilepsy.

“Katie and Cayden’s[sic] Law would allow children with severe epilepsy to participate in a clinical trial using cannabidiol, a marijuana derivative with less than a .3 level of THC to help with seizures, headaches and other effects of various epilepsy-associated ailments,” Echols said. “Cannabidiol is very high in the CBD content, but very low in the THC content, which is the component that gives users the feeling of being ‘high’.”

The bill passed in the House by a vote of 99-2 earlier this year and is now headed to a vote of the full Senate.


See a mistake? Report a typo.

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.